A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors

Inclusion Criteria: * Have signed written informed consent form voluntarily. * Histologically or cytologically documented advanced solid tumor that is refractory/relapsed/intolerant to standard therapies, or for which no effective standard therapy is available, or subject refuses standard therapy. * Have radiologically measurable disease based on RECIST 1.1 * ECOG of 0 or 1. * Estimated life expectancy of ≥3 months. * Adequate organ function. * Have agreed to take effective contraception from the date of signing the informed consent form until 120 days after the last administration. Exclusion Criteria: * have been diagnosed other advanced tumors within 2 years before the first use of the study drug, except for the cured localized tumors. * with active central nervous system metastasis, cancerous meningitis, or spinal cord compression. * Prior use of any anti-VEGF or anti-VEGFR antibodies. * Receipt of anti-tumor treatment, other study drug, major surgery, or serious infection within 4 weeks prior to C1D1 (Cycle 1 Day1, the first dose of study drug). * Have received central venous catheterization within 7 days prior to C1D1. * Severe or uncontrolled cardiovascular and cerebrovascular diseases. * Uncontrolled hypertension. * have a high risk of bleeding. * Uncontrolled gastrointestinal diseases. * Uncontrolled pleural/pericardial or peritoneal effusion. * Have occurred any thromboembolic event, non-gastrointestinal fistula or female genital tract fistula within 6 monthsprior to C1D1. * With cirrhosis of Child-Pugh B or C. * Active or unstable viral hepatitis; or active tuberculosis. * Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * received live vaccines prior 30 days within the first dose. * take apart in other clinical studies at the same time. * known to be allergic to any component of AK109, other monoclonal antibodies or any therapeutic protein. * mental illness, drug abuse, or alcohol dependence that may affect compliance with the test requirements. * Any treatment risk or condition that interferes with the study by the investigator judged.